Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AstraZeneca plc (AZN) vs Banco Santander SA (SAN) Price & Performance

AstraZeneca plcTrade
Banco Santander SATrade

Price performance (Past 24H)

Key statistics

AstraZeneca plc vs Banco Santander SA — how do they compare? AstraZeneca plc trades at $158.62 (market cap $248.14B), while Banco Santander SA trades at $14.8 (market cap $211.63B). The key difference: AstraZeneca plc is the larger of the two by market cap, and AstraZeneca plc pays the higher dividend (2.01%). Which is the better fit depends on your goals.

AZNSAN
Market Cap
$248.14B$211.63B
Sector
HealthFinancials
52-Week High
$209.48$14.71
52-Week Low
$147.06$9.37
Enterprise Value
$275.41B
Dividend Yield
2.01%1.89%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AstraZeneca plc

AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.

The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.

Banco Santander SA

Santander (SAN) trades at $14.80, up 0.75% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a 26.25% net income margin and a P/E of 14.4. Recent news includes Federal Reserve approval for its $12 billion acquisition of Webster Bank, expected to close in August 2026, which may enhance its US market presence.

The outlook is positive, supported by analyst consensus (64% buy ratings) and record profitability. Key risks include volatile cash flows, with negative net cash flow in 2024, and integration challenges from the Webster deal. Revenue growth remains a catalyst, but investors should monitor execution risks and macroeconomic pressures on banking sectors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AstraZeneca plc

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.

Read more on AZN

About Banco Santander SA

Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.

Read more on SAN